Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated seasonal influenza vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The trivalent inactivated seasonal influenza vaccine (TIV) is a biologic vaccine used for the active immunization against seasonal influenza. It contains inactivated (killed) virus particles or purified surface glycoproteins (hemagglutinin and neuraminidase) from three distinct influenza strains: typically two influenza A subtypes (A/H1N1 and A/H3N2) and one influenza B lineage. The specific strains included in the vaccine are updated annually based on World Health Organization (WHO) recommendations to match the predicted circulating viruses for the upcoming season. TIV works by stimulating the immune system to produce hemagglutinin-inhibiting antibodies and memory B-cell responses, which neutralize the virus and prevent it from infecting host cells. While quadrivalent vaccines (QIV) have become more common in many markets, TIV remains a foundational tool in global influenza prevention strategies.
- Brand names
- FluzoneFluarixFluvirinAfluriaAgrifluFluLaval
- Other names
- TIVtrivalent influenza vaccineinactivated influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on trivalent inactivated seasonal influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated seasonal influenza vaccine.